“Akseli Hemminki”的意思、由来-开放百科全书

Akseli Hemminki {{Birth date and age|1973|7|27}} (Helsinki) is a Finnish specialist in Oncology and Radiotherapy, Professor of Oncology and founder of two biotechnology companies.

Career

Akseli Hemminki worked in University of Alabama at Birmingham in 2000-2002, first as a post doctoral researcher and later as a Research Assistant Professor. Soon after his return to Finland in 2002 he founded his own research group in University of Helsinki, Cancer Gene Therapy Group^[1] which he is still leading. In 2007-2013 Hemminki worked as a K. Albin Johansson Research Professor.^[2] In 2015 he was appointed as a Jane and Aatos Erkko Professor of Oncology for five years period.^[3] Akseli Hemminki has been selected as an "Outstanding Young Person of the World" by Junior Chamber International in 2006.^[4]

Besides his scientific career Hemminki has worked as a physician in 1998-1999, as a resident in 2003-2007 and as a specialist in oncology since 2007 in HUS (Hospital district of Helsinki and Uusimaa)^[5] and Docrates Cancer Center.^[6]

Research

Akseli Hemminki’s research focuses on cancer immunotherapy and especially on oncolytic adenoviruses.^[7] The goal of his research group is to create a new oncolytic adenovirus based treatment for cancers with no available curative treatment at the moment.^[8]^[9] The key finding of the group is that oncolytic viruses – besides lyse tumor cells by oncolysis – trigger immune response towards the tumor.^[10] Recently, Hemminki’s group has focused on attempting to enable T-cell therapy of solid tumors with oncolytic adenoviruses.^[11]

To facilitate setting up clinical trials Akseli Hemminki has founded two biotechnology companies: 2008 Oncos Therapeutics (merged with Targovax ASA in 2015^[12]^[13]) and 2013 TILT Biotherapeutics.^[14]^[15]^[16] Oncos completed the first oncolytic virus trial ever performed in Northern Europe in fall 2013.^[17] Over 300 patients have been treated with cancer drugs developed by Hemminki.^[18]^[19]^[20]^[21]

References

1. ^Cancer Gene Therapy Group
2. ^“Finnish Cancer Institute funded Professorship awarded to Akseli Hemminki (in Finnish)”, Biomedicum Helsinki webpages. Retrieved October 3, 2016.
3. ^“University of Helsinki Professors (in Finnish)”, University of Helsinki web-pages. Retrieved October 3, 2016.
4. ^“JCI Toyp Honeree List”, Junior Chamber International web-pages. Retrieved December 22, 2016.
5. ^HUS
6. ^[https://www.docrates.com/en/professionals/ Docrates Cancer Center Professionals]
7. ^"Now the man who revolutionized cancer treatment is looking to help people", Kemianteollisuus webpages, "Views on Chemistry". Retrieved December 22, 2016.
8. ^"Developing New Treatments for Cancers" Projects Magazine. Retrieved December 22, 2016.
9. ^"Using viruses to help battle cancer" HighTech Finland webpages. Retrieved December 22, 2016.
10. ^{{Cite journal |pmid = 20484030|year = 2010|last1 = Cerullo|first1 = V.|title = Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients|journal = Cancer Research|volume = 70|issue = 11|pages = 4297–309|last2 = Pesonen|first2 = S.|last3 = Diaconu|first3 = I.|last4 = Escutenaire|first4 = S.|last5 = Arstila|first5 = P. T.|last6 = Ugolini|first6 = M.|last7 = Nokisalmi|first7 = P.|last8 = Raki|first8 = M.|last9 = Laasonen|first9 = L.|last10 = Särkioja|first10 = M.|last11 = Rajecki|first11 = M.|last12 = Kangasniemi|first12 = L.|last13 = Guse|first13 = K.|last14 = Helminen|first14 = A.|last15 = Ahtiainen|first15 = L.|last16 = Ristimäki|first16 = A.|last17 = Räisänen-Sokolowski|first17 = A.|last18 = Haavisto|first18 = E.|last19 = Oksanen|first19 = M.|last20 = Karli|first20 = E.|last21 = Karioja-Kallio|first21 = A.|last22 = Holm|first22 = S. L.|last23 = Kouri|first23 = M.|last24 = Joensuu|first24 = T.|last25 = Kanerva|first25 = A.|last26 = Hemminki|first26 = A.|doi = 10.1158/0008-5472.CAN-09-3567}}
11. ^{{Cite journal |pmid = 25977260|year = 2015|last1 = Tähtinen|first1 = S.|title = Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor|journal = Cancer Immunology Research|volume = 3|issue = 8|pages = 915–25|last2 = Grönberg-Vähä-Koskela|first2 = S.|last3 = Lumen|first3 = D.|last4 = Merisalo-Soikkeli|first4 = M.|last5 = Siurala|first5 = M.|last6 = Airaksinen|first6 = A. J.|last7 = Vähä-Koskela|first7 = M.|last8 = Hemminki|first8 = A.|doi = 10.1158/2326-6066.CIR-14-0220-T}}
12. ^Targovax ASA
13. ^"Targovax and Oncos Therapeutics join forces to create a Nordic leader within immuno-oncology - PRESS RELEASE" Retrieved December 22, 2016.
14. ^TILT Biotherapeutics Ltd
15. ^"TILT Biotherapeutics Secures 10 M ($10.6M) for Viral Cancer T-Cell Immunotherapy" Wave3 News. Retrieved December 22, 2016.
16. ^"Start-up Story. Tilt Biotherapeutics - Express to solid tumours" European Biotechnology Life Science and Industry Magazine. Retrieved December 22, 2016.
17. ^[https://clinicaltrials.gov/ct2/show/NCT01598129 “ONCOS-102 (previously CGTG-102) for Therapy of Advanced Cancers”] Clinicaltrials.gov. Retrieved October 3, 2016.
18. ^"ASGCT News, Summer 2011. Cancer Gene & Cell Therapy, Symposium 444". Retrieved December 22, 2016.
19. ^{{Cite journal |pmc = 4801451|year = 2015|last1 = Hemminki|first1 = O.|title = A century of oncolysis evolves into oncolytic immunotherapy|journal = Oncoimmunology|volume = 5|issue = 2|pages = e1074377|last2 = Hemminki|first2 = A.|pmid = 27057442|doi = 10.1080/2162402X.2015.1074377}}
20. ^{{Cite journal |pmc = 3914551|year = 2014|last1 = Hemminki|first1 = A.|title = Oncolytic Immunotherapy: Where Are We Clinically?|journal = Scientifica|volume = 2014|pages = 1–7|pmid = 24551478|doi = 10.1155/2014/862925}}
21. ^{{Cite journal |pmc = 4791966|year = 2016|last1 = Ranki|first1 = T.|title = Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers|journal = Journal for Immunotherapy of Cancer|volume = 4|pages = 17|last2 = Pesonen|first2 = S.|last3 = Hemminki|first3 = A.|last4 = Partanen|first4 = K.|last5 = Kairemo|first5 = K.|last6 = Alanko|first6 = T.|last7 = Lundin|first7 = J.|last8 = Linder|first8 = N.|last9 = Turkki|first9 = R.|last10 = Ristimäki|first10 = A.|last11 = Jäger|first11 = E.|last12 = Karbach|first12 = J.|last13 = Wahle|first13 = C.|last14 = Kankainen|first14 = M.|last15 = Backman|first15 = C.|last16 = von Euler|first16 = M.|last17 = Haavisto|first17 = E.|last18 = Hakonen|first18 = T.|last19 = Heiskanen|first19 = R.|last20 = Jaderberg|first20 = M.|last21 = Juhila|first21 = J.|last22 = Priha|first22 = P.|last23 = Suoranta|first23 = L.|last24 = Vassilev|first24 = L.|last25 = Vuolanto|first25 = A.|last26 = Joensuu|first26 = T.|pmid = 26981247|doi = 10.1186/s40425-016-0121-5}}